Barbara is a 61-year-old female diagnosed with multiple myeloma, IgG Kappa, ISS stage II (C90.0), with ongoing back pain and to have extensive lyic lesions and spinal fractures. Previously, Barbara was treated Pom/Dara/Dex, Vel/Dex, revlimid, autologous transplant, velcade and dexamethasone, but still experienced disease progression. She has symoptomatic progression on Pom/dara/dex with new pain and weakness, along with a marrow that shows t(11:14). Barbara is in need of a more combative treatment. Although Barbara suffers from multiple myeloma not having achieved remission and Venclexta is not FDA approved for this treatment, the FDA does state “it’s labeling is not intended to limit the prescribing of medications of off-label uses, then
